Wan Yihong, Nordeen Steven K
Department of Pathology, Program in Molecular Biology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
Recent Prog Horm Res. 2003;58:199-226. doi: 10.1210/rp.58.1.199.
Glucocorticoids and progestins bind to receptors that share many structural and functional similarities, including virtually identical DNA recognition specificity. Nonetheless, the two hormones mediate very distinct biological functions. For example, progestins are associated with the incidence and progression of breast cancer, whereas glucocorticoids are growth suppressive in mammary cancer cells. To understand the mechanisms that engender biological specificity, we have employed two systematic approaches to identify genes that are differentially regulated by the two hormones. The first strategy is to utilize Affymetrix oligonucleotide arrays to compare glucocorticoid- and progestin-regulated gene expression in a human breast cancer cell line. This global analysis reveals that the two hormones regulate overlapping but distinct sets of genes, including 31 genes that are differentially regulated. Surprisingly, the set of differentially regulated genes was almost as large as the set of genes regulated by both hormones. Examination of the set of differentially regulated genes suggests mechanisms behind the distinct growth effects of the two hormones in breast cancer. The differential regulation of four genes representing different regulatory patterns was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and Northern blot analyses. Treatment with cycloheximide or mifepristone (RU486) indicates that the regulation is a primary, receptor-mediated event. The second strategy is to employ a retroviral promoter trap and Cre/loxP-mediated, site-specific recombination to identify genes that are differentially regulated by glucocorticoids and progestins. A mouse fibroblast cell line (4F) stably expressing both glucocorticoid receptor (GR) and progesterone receptor (PR) and containing a single copy of a multifunctional selection plasmid was generated. This line was transduced with a self-inactivating retroviral promoter trap vector carrying coding sequences for Cre-recombinase (Cre) in the U3 region. Integration of the provirus places Cre expression under the control of genomic flanking sequence. Activation of Cre expression from integration into active genes results in a permanent switch between the selectable marker genes that convert the cells from neomycin resistant to hygromycin resistant. Selection for hygromycin resistance after hormone treatment yields recombinants in which Cre sequences in the U3 region are expressed from hormone-inducible, upstream cellular promoters. Because Cre-mediated recombination is a permanent event, the expression of the selectable marker genes is independent of ongoing Cre expression. Thus, this system permits the identification of genes that are transiently or weakly induced by hormone. Detailed analyses of genes identified in these studies will furnish a mechanistic understanding of differential regulation by glucocorticoids and progestins.
糖皮质激素和孕激素与具有许多结构和功能相似性的受体结合,包括几乎相同的DNA识别特异性。尽管如此,这两种激素介导的生物学功能却截然不同。例如,孕激素与乳腺癌的发生和进展相关,而糖皮质激素对乳腺癌细胞具有生长抑制作用。为了了解产生生物学特异性的机制,我们采用了两种系统方法来鉴定受这两种激素差异调节的基因。第一种策略是利用Affymetrix寡核苷酸阵列比较人乳腺癌细胞系中糖皮质激素和孕激素调节的基因表达。这种全局分析表明,这两种激素调节重叠但不同的基因集,包括31个差异调节的基因。令人惊讶的是,差异调节基因集几乎与受两种激素共同调节的基因集一样大。对差异调节基因集的研究揭示了这两种激素在乳腺癌中产生不同生长效应背后的机制。通过逆转录聚合酶链反应(RT-PCR)和Northern印迹分析证实了代表不同调节模式的四个基因的差异调节。用放线菌酮或米非司酮(RU486)处理表明这种调节是一种主要的、受体介导的事件。第二种策略是采用逆转录病毒启动子陷阱和Cre/loxP介导的位点特异性重组来鉴定受糖皮质激素和孕激素差异调节的基因。构建了一个稳定表达糖皮质激素受体(GR)和孕激素受体(PR)且含有单拷贝多功能选择质粒的小鼠成纤维细胞系(4F)。用一个在U3区域携带Cre重组酶(Cre)编码序列的自失活逆转录病毒启动子陷阱载体转导该细胞系。前病毒的整合使Cre表达受基因组侧翼序列的控制。Cre表达从整合到活性基因中激活,导致选择标记基因之间的永久转换,从而将细胞从对新霉素抗性转换为对潮霉素抗性。激素处理后选择潮霉素抗性产生重组体,其中U3区域的Cre序列由激素诱导的上游细胞启动子表达。由于Cre介导的重组是一个永久性事件,选择标记基因的表达与持续的Cre表达无关。因此,该系统允许鉴定受激素瞬时或弱诱导的基因。对这些研究中鉴定的基因进行详细分析将有助于从机制上理解糖皮质激素和孕激素的差异调节。